Skvarka Jan has filed 5 insider transactions across 2 companies since June 2024.
Most recent transaction: a grant/award of 57603 shares of Zentalis Pharmaceuticals, Inc. ($ZNTL) on June 17, 2025.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 17, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Skvarka Jan | Director | A | Common Stock | 57603 | $0.00 | 207,154.0000 | 71,811,508 | 38.52% | 0.08% |
| June 13, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Skvarka Jan | Not found | A | Stock Option (Right to Buy) | 30700 | $0.00 | 30,700.0000 | 73,910,026 | 9999.99% | 0.04% |
| Jan. 31, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Skvarka Jan | Director | P | Common Stock | 60000 | $1.72 | 149,551.0000 | 0 | 67.00% | 0.00% |
| June 21, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Skvarka Jan | Director | A | Common Stock | 41581 | $0.00 | 89,551.0000 | 0 | 86.68% | 0.00% |
| June 12, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Skvarka Jan | Not found | A | Stock Option (Right to Buy) | 22100 | $0.00 | 22,100.0000 | 51,396,961 | 9999.99% | 0.04% |